These results suggest that high intracellular NAD+ levels caused by the upregulation of NAMPT contribute to disease exacerbation in pancreatic cancer and that resistance to PARP inhibitors may be induced in various cancer patients including PDAC by the administration of PARP inhibitors. The gene discussed is PARP1; the disease is familial pancreatic carcinoma.